You are here
Publications
Popular Publications
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding
18 June 2020The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
National Efficient Price Determination 2020–21
2 March 2020The Independent Hospital Pricing Authority (IHPA) is established under the National Health Reform Act 2011 (Cwlth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this National Efficient Price Determination 2020–21 (Determination):
National Efficient Price Determination 2016-17
1 March 2016The Independent Hospital Pricing Authority (Pricing Authority) is established under the National Health Reform Act 2011 (Cth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this National Efficient Price (NEP) Determination 2016 (Determination):
National Efficient Price Determination 2012-13
30 May 2012The Independent Hospital Pricing Authority (Pricing Authority) is established under the National Health Reform Act 2011 (Cth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this National Efficient Price Determination 2012-2013 (Determination):
(a) to determine the national efficient price for health care services provided by public hospitals where the services are funded on an activity basis;